FIELD: medicine.
SUBSTANCE: invention refers to crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]benzoic acid 
(formula I), pharmaceutical compositions and dosage forms containing these crystalline forms, as well as to methods for preparing such crystalline forms and methods for using them for treating, preventing a disease or a disorder associated with premature terminating codon. There are prepared new crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]benzoic acid which are non-absorbent and which can find application in medicine for treating or preventing such diseases or disorders as type III mucopolysaccharidosis, hemophilia A, hemophilia B, neurofibromatosis 1, neurofibromatosis 2, Parkinson's disease, cystic fibrosis, macular degeneration, cephalooculocutaneous telangiectasis, retinitis pigmentosa, tuberous sclerosis, Duchenne muscular dystrophy and Marfan's syndrome, cancer.
EFFECT: higher effectiveness of using the compounds and a method of treating.
46 cl, 11 dwg, 9 tbl
| Title |
Year |
Author |
Number |
| CRYSTALLINE TOSYLATE SALT (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8-9-DIHYDRO-2H-PYRIDO[4,3,2-de]PHTHALAZIN-3(7H)-ONE |
2011 |
- Van Bin
- Chu Deniel
- Lyu Yunbo
- Pen Shichun
|
RU2598606C2 |
| CRYSTAL FORM OF PARP-1 INHIBITOR AND ITS PRODUCTION METHOD |
2018 |
- Li, Wenhai
- Zhang, Quanliang
- Qiu, Zhenjun
- Li, Zhengming
|
RU2792620C2 |
| METHODS OF DOSING ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSIVE THERAPY |
2007 |
- Khiravat Samit
- Miller Langdon
|
RU2462247C2 |
| NOVEL SOLID FORMS (2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(((4AR,10AR)-7-HYDROXY-1-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO[G]QUINOLIN-6-YL)OXY)TETRAHYDRO-2H-PYRAN-2-CARBOXYLIC ACID |
2020 |
- Jensen, Klaus, Gervig
- Jorgensen, Morten
- Dzhukhl, Martin
- Kvaerno, Lisbet
- De Diego, Khejdi, Lopez
- Fredkholt, Karin
- Terkelsen, Frans Dennis
- Frikhed, Tobias Gilling
- Yakobsen, Mikkel Fog
|
RU2820501C2 |
| POLYMORPHIC MODIFICATIONS OF N-[(3-FLUORO-4-METHOXYPYRIDINE-2-YL)METHYL]-3-(METHOXYMETHYL)-1-({ 4-[(2-OXOPYRIDINE-1-YL)METHYL]PHENYL} METHYL)PYRAZOLE-4-CARBOXAMIDE AND THEIR SALTS |
2017 |
- Beaton, Haydn
- Crowe, David Malcolm
- Edwards, Hannah Joy
- Griffiths-Haynes, Nicholas James
|
RU2756273C2 |
| METHOD FOR PRODUCING FUNCTIONAL PROTEIN FROM DNA HAVING NONSENSE MUTATIONS, AND TREATING ASSOCIATED DISORDERS |
2007 |
- Al'Msted Nil G.
- Chen Guangming
- Khiravat Samit
- Khvang Seongvoo
- Karp Gari M.
- Miller Langdon
- Moon Joung-Choon
- Ren Khongiu
- Takasugi Dzhems Dzh.
- Uehlch Ehllen M.
- Uajld Richard Dzh.
- Kennedi Pol
|
RU2462246C2 |
| CRYSTAL FORMS OF TRIAZOLOPYRIMIDINE COMPOUND |
2017 |
- Liu, Bo
- Huang, Ying
- Mao, Liang
- Wang, Long
- Waykole, Liladhar Murlidhar
- Zhang, Lijun
|
RU2754856C2 |
| MANUFACTURE OF 2-(5-BROMO-4(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID |
2013 |
- Gunik Esmir
- Gelvin Gabriel
|
RU2666549C2 |
| CRYSTALLINE FORM OF MALEATE OF CONDENSED PYRIDINE DERIVATIVE AND METHODS FOR USE THEREOF |
2016 |
- Hu, Shaojing
- Long, Wei
- Zhou, Liufeng
- Xu, Zhiguo
- Wang, Fei
|
RU2712280C2 |
| POLYMORPHS OF 2-(4-(2-(1-ISOPROPYL-3-METHYL-1H-1,2,4-TRIAZOL-5-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPANAMIDE, METHODS OF PRODUCTION AND PHARMACEUTICAL USES THEREOF |
2014 |
|
RU2658009C2 |
